` ESPR (Esperion Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

ESPR
vs
S&P 500

Over the past 12 months, ESPR has underperformed S&P 500, delivering a return of -68% compared to the S&P 500's 12% growth.

Stocks Performance
ESPR vs S&P 500

Loading

Performance Gap
ESPR vs S&P 500

Loading
ESPR
S&P 500
Difference

Performance By Year
ESPR vs S&P 500

Loading
ESPR
S&P 500
Add Stock

Competitors Performance
Esperion Therapeutics Inc vs Peers

S&P 500
ESPR
LLY
JNJ
NOVO B
ROG
Add Stock

Esperion Therapeutics Inc
Glance View

Market Cap
157.7m USD
Industry
Pharmaceuticals

Esperion Therapeutics, Inc. is a pharmaceutical company. The company is headquartered in Ann Arbor, Michigan and currently employs 218 full-time employees. The company went IPO on 2013-06-24. The firm is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease (ASCVD), or heterozygous familial hypercholesterolemia (HeFH). The firm's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NEXLIZET and NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.

ESPR Intrinsic Value
4.834 USD
Undervaluation 83%
Intrinsic Value
Price
Back to Top